Related Experiment Video
Updated: Aug 17, 2026

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay
Published on: September 9, 2012
Recombinant factor IX (BeneFix) by adjusted continuous infusion: a study of stability, sterility and clinical
P Chowdary1, H Dasani, J A Jones
1Arthur Bloom Centre for Haemophilia, Department of Haematology, University Hospital of Wales, Cardiff, UK.
Abstract:
The safety and efficacy of adjusted continuous infusion (CI) of recombinant factor IX (FIX; BeneFix) was assessed in vitro and in a clinical study. BeneFix was reconstituted at 100 IU mL-1 with or without unfractionated heparin (4 U mL-1) and stored at either 4 degrees C or room temperature. Reconstituted BeneFix retained at least 90% activity over 14 days if stored at 4 degrees C but stability was reduced at room temperature. BeneFix reconstituted in a sterile pharmacy was free of bacterial contamination. Six patients with haemophilia B received seven CIs of BeneFix to cover routine surgery and severe bleeding episodes. The CIs lasted between 3 and 10 days. In all cases, haemostasis was excellent and the desired therapeutic FIX level was easily maintained. No thrombotic episodes or inhibitor development occurred but two patients developed thrombophlebitis at the infusion site when heparin was not added to the infusion. BeneFix is not currently licensed for CI and we suggest that studies to enable licensing should be established as soon as possible.
Related Concept Videos
Steady State Concentration
Most drugs are administered in repeated doses at fixed intervals or through continuous intravenous...
One-Compartment Model: IV Infusion
The one-compartment model for IV infusion uses mathematical equations to describe the rate of change in drug quantity in the body. At steady-state or infusion equilibrium, the drug input...
Biopharmaceutical Factors Influencing Drug Product Design: Overview
Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence
Drug Accumulation During Multiple Dosing: Intermittent IV Infusions
Modified-Release Drug Delivery Systems: Rate-Programmed I

